FDA Action Roundup: December 2025 - New Approvals, expansions & A Notable Setback
December 2025 proved too be a dynamic month for pharmaceutical approvals and regulatory decisions from the Food and Drug Administration. Several key medications gained the green light, expanding treatment options for conditions ranging from leukemia to gonorrhea. However, a notable setback also emerged for a promising multiple sclerosis drug. Here’s a detailed look at the major developments.
Oncology Advancements
Full Approval for Epkinly. Epkinly (epcoritamab-bysp) received full FDA approval for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This follows accelerated approval granted in 2023, solidifying its place as a valuable treatment option.
Infectious Disease Breakthroughs
New Oral Gonorrhea Treatments Arrive. The FDA approved two novel oral treatments for uncomplicated urogenital gonorrhea in quick succession, offering alternatives to traditional injectable antibiotics. This is particularly crucial as antibiotic resistance continues to be a growing concern.
* Blujepa (gepotidacin): Initially approved for uncomplicated urinary tract infections (utis), Blujepa now extends its reach to gonorrhea treatment for patients age 12 and older who cannot tolerate or prefer not to receive injections.
* Nuzolvence (zoliflodacin): Inoviva Specialty Therapeutics’ Nuzolvence, an oral suspension, provides a distinct mechanism of action compared to existing gonorrhea treatments. This offers a crucial new tool in combating this common sexually transmitted infection.
Regulatory Challenges
Setback for Tolebrutinib in Multiple Sclerosis. Sanofi faced a significant hurdle as the FDA delayed its decision on tolebrutinib for non-relapsing secondary progressive multiple sclerosis (MS).
* The FDA indicated the review would extend beyond the initial December 28th target date, with further guidance expected in early 2026.
* Sanofi expressed surprise, noting this represents a “significant and meaningful change in direction” from previous agency feedback.
* This isn’t the first challenge for tolebrutinib, which Sanofi acquired through its $3.7 billion acquisition of Principia Biopharma in 2020, and previously faced trial pauses due to liver injury concerns.
What This Means for You. These FDA actions highlight the ongoing progress in pharmaceutical innovation. You can expect to see expanded treatment options and potentially improved outcomes for a variety of conditions. However, regulatory setbacks remind us that drug development is a complex process, and not every promising therapy will reach the market.
This roundup provides a snapshot of the key regulatory events in December 2025. Staying informed about these developments is crucial for healthcare professionals and patients alike, ensuring you have access to the latest details regarding treatment options and advancements in medical care.